Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

Gilead’s multitarget antibody discovery deal with AbCellera will draw on a growing toolbox, including a humanized mouse model and a bispecifics platform, that the biotech has built over the course of a year in which it went public and gained an authorization for a COVID-19 program shared with Lilly.

AbCellera Biologics Inc. (NASDAQ:ABCL) will create antibodies against up to eight targets chosen by Gilead Sciences Inc. (NASDAQ:GILD). CEO Carl Hansen told BioCentury the agreement is not limited to specific therapeutic areas; he said the biotech “has a line of sight” to Gilead’s first chosen target, and is discussing which others may be added to the deal...